Coronary artery disease

Johnson & Johnson Completes Acquisition of Shockwave Medical

Retrieved on: 
fredag, maj 31, 2024
Biotechnology, Health, Pharmaceutical, Health Technology, Cardiology, Patient, Cardiovascular disease, JNJ, Abiomed, Coronary artery disease, CAD, PAD, Johnson & Johnson, Peripheral artery disease, Death, Electrophysiology, Acquisition, Shock wave, Medtech, IVL, Worldwide, Pharmaceutical industry

Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.

Key Points: 
  • Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
  • Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.
  • We are delighted to welcome the Shockwave team to Johnson & Johnson and look forward to bringing their innovative IVL technology to more patients around the world.”
    Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said, “Completing this acquisition is a significant milestone in the expansion of our leadership position in the medtech industry.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.

Global Multimodal Imaging Market Outlook & Forecast 2024-2029: A Fiercely Competitive Landscape with Canon, GE Healthcare, Koninklijke Philips, Siemens Healthineers, and Shimadzu Dominating - ResearchAndMarkets.com

Retrieved on: 
torsdag, maj 30, 2024
Health, Technology, Hospitals, Health Technology, Radiology, Artificial Intelligence, Pharmaceutical, PET, PET/MRI, Patient, Radiation exposure, Biomedical Research, Metabolism, Coronary artery disease, Hospital, Google Images, Ophthalmology, Molecular imaging, Heart failure, Prevalence, Conditional sentence, PET/MR, MRI, Diagnosis, Disease, Drug development, Brain, Echocardiography, Stroke, Gynaecology, Myocardial perfusion imaging, Ageing, AI, Elective surgery, Research, Face, Epilepsy, Tissue, Cardiology, SPECT, Neurology, PET/CT, DSM-IV codes, Shimadzu, Cardiomyopathy, GE HealthCare, Magnetic resonance, Nuclear medicine, Angiography, SPECT/CT, Obstetrics, Perfusion, Siemens Healthineers, Medical imaging

The global multimodal imaging market is dominated by several key players, each with a significant industry presence and a diverse portfolio of imaging solutions.

Key Points: 
  • The global multimodal imaging market is dominated by several key players, each with a significant industry presence and a diverse portfolio of imaging solutions.
  • Some of the leading players in the market include Canon Medical Systems, GE Healthcare, Koninklijke Philips, Siemens Healthineers, and Shimadzu Corporation.
  • The growing adoption of AI and analytics in diagnostic imaging undoubtedly creates exciting opportunities for the multimodal imaging market.
  • The global multimodal imaging market encompasses various end-users, including hospitals, diagnostic imaging centers, research institutions, and others.

Creating better health care with artificial intelligence tools

Retrieved on: 
onsdag, maj 29, 2024
Patient, Coronary artery disease, Intelligence, University, Primary care, Google Images, Water, Privacy, Entrepreneurship, Investment, Artificial intelligence, Safety, Stroke, Alberta Innovates, Ethics, AISA, Research, Autumn, Physician, Agriculture, Access, Medical device

Ten university research teams and two private companies are being granted $9.5M through a new program to address barriers that prevent using artificial intelligence in health care.

Key Points: 
  • Ten university research teams and two private companies are being granted $9.5M through a new program to address barriers that prevent using artificial intelligence in health care.
  • The Enabling Better Health Through Artificial Intelligence program was launched in the Fall of 2023 with a total budget of $8M.
  • The goal is faster and better health care for Albertans and the development of new technologies right here in Alberta that can be exported around the world.”
    “Mikata Health is pleased to be a recipient of the AI Better Health program.
  • Digital Health Tools & Artificial Intelligence for Understanding and Addressing Social Determinants of Health in Primary Care.

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Retrieved on: 
torsdag, maj 23, 2024
Risk, Obesity, ESS, ResMed, Ageing, SAN, ATS, Woman, ASV, Therapy, University of California, ASX, Plan, Health care, LVEF, Coronary artery disease, Sleep, Grenoble Alpes University, Literature review, Natural language processing, Conference, CSA, Circulatory system, Meta-analysis, BMI, AHI, Clinical trial, NIV, Obstructive sleep apnea, Qualitative Research (journal), Comorbidity, Depression, NYHA, Sleep disorder, Hospital, Research, OSA, COPD, Central sleep apnea, PAP, Patient, Education, Qualitative, RMD, Prevalence, University, Overalls, Mortality, Death, Abstract, Economy, Adaptation, Quality of life, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits. The studies were among 26 supported by ResMed (NYSE: RMD, ASX: RMD) in collaboration with leading scientists including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany.

Key Points: 
  • The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
  • Several studies demonstrated findings showing continued effectiveness of PAP therapies for patients with sleep disorder conditions like obstructive sleep apnea.
  • This finding demonstrates a correlation between the use of PAP therapy and a reduction in use of healthcare resources.
  • Two studies evaluated the effects of Adaptive Servo-Ventilation (ASV) therapy in two populations, patients with TE-CSA and patients on long-term opioid therapy.

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

Retrieved on: 
torsdag, maj 16, 2024
Plan, Education, Qualitative Research (journal), Qualitative, Marriott Marquis, Coronary artery disease, Sleep apnea, Obstructive sleep apnea, Literature review, Depression, Natural language processing, ResMed, Mortality, Harbor, SDCC, Circulatory system, OSA, Patient, Risk, San Diego Convention Center, COPD, ATS, Abstract, Meta-analysis, Research, Economy, Control, AHI, Clinical trial

Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101

Key Points: 
  • Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101
    Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101
    Research: 26 ResMed-supported abstracts will be presented at ATS.
  • Full list below.
  • Highlights:
    Presented by Monica Mallampalli, Chief Executive Officer at Alliance of Sleep Apnea Partners, and Carlos Nunez, ResMed Chief Medical Officer
    Booth #1442: Featuring ResMed’s latest innovations in respiratory care:
    AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
    Complete list of ResMed sponsored studies to be presented at ATS 2024:
    Impact of CPAP Termination on Permanent Work Disability in Obstructive Sleep Apnea: A French Nationwide Alaska Database Analysis
    Using Natural Language Processing for Qualitative Research: Insights From a Real-world Analysis
    All-cause Mortality in Obstructive Sleep Apnea: Systematic Literature Review Including Randomised Trials and Confounding Adjusted Non-randomised Controlled Studies and Meta-analysis of Positive Airway Pressure Treatment
    Hypoxic Burden but Not AHI Predicts Risk of Cardiovascular Events: A Secondary Analysis of the RICCADSA Clinical Trial
    The Economic and Health Burden of COPD in North America Through 2050: A Scenario Analysis Based on Two Large Data Sources
    Less REM Sleep Predicts Mortality in Adults With Coronary Artery Disease and Obstructive Sleep Apnea: The RICCADSA Trial
    Gender Specific Differences in a National Sample of Individuals with Comorbid Insomnia, Obstructive Sleep Apnea (OSA), and Depression
    A Mixed-methods Exploration of Patient Perspectives on Pap Therapy Initiation: Implications for Improved Outreach and Education

HeartFlow's Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study

Retrieved on: 
onsdag, maj 15, 2024
Patient, Coronary artery disease, Cardiovascular disease, IVUS, Plaque, FDA, Death, Anatomy, Woman, Artificial intelligence, Physician, Physiology, Medical imaging

REVEALPLAQUE aimed to evaluate HeartFlow’s non-invasive plaque technology , an automated, deep learning-based method for identifying, characterizing, and segmenting plaque in the coronary arteries.

Key Points: 
  • REVEALPLAQUE aimed to evaluate HeartFlow’s non-invasive plaque technology , an automated, deep learning-based method for identifying, characterizing, and segmenting plaque in the coronary arteries.
  • Understanding the volume and composition of plaque allows physicians to ensure appropriate medical treatment, which could be life changing for patients.
  • This was an independent, blinded, core lab adjudicated study to determine the accuracy of HeartFlow’s AI Plaque Analysis compared head-to-head with IVUS.
  • The plaque technology is based on HeartFlow’s proprietary deep learning-enabled algorithms, which have been trained on more than 15 million coronary CT images.

Global Enzyme Contract Manufacturing Market Analysis 2024: $4.82 Billion Industry Driven by Increasing Demand Across Multiple Verticals, Coupled with Advancements in Biotechnology and Fermentation - ResearchAndMarkets.com

Retrieved on: 
måndag, maj 20, 2024
Biotechnology, General Health, Health, Science, Research, Diabetes, Coronary artery disease, Obesity, Drug development, Food, Vaccine, Biopharmaceutical, Arrhythmia, World Health Organization, Biofuel, Pharmaceutical manufacturing, Porter's five forces analysis, Enzyme, Epidemiology, Disease, USD, Peripheral artery disease, Hypertension, Cancer, Death, Incidence, Protein engineering, Cardiovascular disease, WHO, Biocatalysis, Non-communicable disease, Risk, DNA, Organization, Plant, Prevalence, Growth, Fermentation, Mortality, Textile, SWOT, Fine chemical

The Global Enzyme Contract Manufacturing market showcased growth at a CAGR of 8.19% during 2020-2023.

Key Points: 
  • The Global Enzyme Contract Manufacturing market showcased growth at a CAGR of 8.19% during 2020-2023.
  • The market for enzyme contract manufacturing has seen significant growth due to the increasing demand for enzymes in various industries, coupled with advancements in biotechnology and fermentation technologies.
  • The report analyses the Enzyme Contract Manufacturing Market by Application (Industrial Enzyme, Specialty Enzyme).
  • The report analyses the Enzyme Contract Manufacturing Market by End-Use (Food and Beverages, Detergents, Pharmaceutical Manufacturing, Other End-Use).

GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease

Retrieved on: 
tisdag, maj 14, 2024
Health, Medical Devices, Health Technology, General Health, Radiology, Cardiology, Biotechnology, Patient, Coronary artery disease, Cardiovascular disease, CAD, Angina, Hospital, Chest pain, Risk, Heart, Congress, Diagnosis, Disease, Death, AI, Research, Percutaneous coronary intervention, GE HealthCare, Splenic infarction, PCI, Myocardial infarction, Pulse, Medis, QFR, Physiology, Medical imaging

Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD).

Key Points: 
  • Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD).
  • The collaboration seeks to provide access to emerging technologies, like Medis QFR, while also reducing complexity in the cath lab to improve the operating environment for clinicians.
  • “In the assessment of coronary artery disease, QFR represents a significant advancement in how efficiently it can provide critical insights.
  • Medis’ QFR is a proprietary solution that delivers image-based physiology of coronary obstructions based on angiography imaging analysis alone.

EuroPCR 2024: Late-Breaking Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years

Retrieved on: 
tisdag, maj 14, 2024
Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Elixir, RCT, Patient, Coronary artery disease, Catheter, Plaque, TLF, LAD, Division, Catheterization laboratory, TVF, Medicine, Medical imaging

The data were presented at a late-breaking clinical session during the EuroPCR 2024 conference in Paris.

Key Points: 
  • The data were presented at a late-breaking clinical session during the EuroPCR 2024 conference in Paris.
  • Clinical results show statistically significant benefit with DynamX bioadaptor over Resolute Onyx at two years:
    65% reduction in TLF rate (1.9% versus 5.5%; p=0.046).
  • “We are beyond thrilled with these findings from the BIOADAPTOR RCT,” said Motasim Sirhan, CEO of Elixir Medical.
  • These exceptional patient clinical outcomes further validate that the bioadaptor is truly a transformative technology for coronary artery disease treatment.”

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
Genetics, Liver disease, Coronary artery disease, Research, N-Acetylgalactosamine, Weight loss, Doctor of Philosophy, Webcast, SVP, DSM-IV codes, CSO, Biomarker, Drug discovery, AATD, RNA editing, Activin and inhibin, Facial muscles, Pharmacokinetics, LNP, SAD, GSK, Serum, Duchenne muscular dystrophy, HTT, Cerebrospinal fluid, MASH, Weight, Safety, Health, RNA, Obesity, Human, Therapy, HD, Central nervous system, Clinical trial, ED50, Small RNA, Stanford University, Lof, Genomics, Exon, Science, Senior, Patient, Cardiovascular disease, MBA, PD, Lipolysis, Q&A, Pharmaceutical industry

ET today

Key Points: 
  • ET today
    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Revenue was $12.5 million for the first quarter of 2024, as compared to $12.9 million in the first quarter of 2023.
  • Net loss was $31.6 million for the first quarter of 2024, as compared to $27.4 million for the first quarter of 2023.
  • ET to review the first quarter 2024 financial results and pipeline updates.